Replies to post #40 on Ambrx Biopharma Inc (AMAM)

[MT101]

Agreed. But I think a lot sooner than a year

[axelvento]

Two Phase 3 studies and one registration enabled Phase 2 study with ARX788 (ACE-Breast-02, ACE-Gastric-02, and ACE-Breast-08) conducted by Amrbrx’s partner, NovoCodex Biopharmaceuticals, are ongoing in China with projected readouts in 2023.